Pharmaceutical Commerce
@PharmaCommerce
Followers
3K
Following
1K
Media
2K
Statuses
8K
Pharmaceutical Commerce magazine: Business strategies for pharma/bio success.
Joined April 2010
The December issue is here! Explore pharma's market access transformation, MFN's long-term impact, and much more. Interactive version👉 https://t.co/ptAI19grWM HTML version: https://t.co/40f9KmToqb
0
0
0
DTP is reshaping pharma’s access model—speed up starts, cut friction, and build real patient trust. Discover why the brands that win will treat DTP as core infrastructure, not support. Read more in Part 3 of the series: https://t.co/ekhbJ4tUQz
#PharmaInnovation
0
0
0
Laying the tracks for advanced med management 🛤️ “Every good revolution in healthcare starts with a good framework,” @Colin_Banas tells @PharmaCommerce. Read about what this means for electronic PA, RTPB, and transparency for providers and patients ➡️
pharmaceuticalcommerce.com
In the second part of his Pharma Commerce video interview, Colin Banas, MD, DrFirst’s chief medical officer, points out that while real-time benefit tools are improving coverage visibility at the...
0
2
6
CEVA Logistics plans to acquire Fagioli Group, expanding its project #logistics capabilities across heavy-lift, hauling, and end-to-end delivery. The move adds specialized engineering talent and strengthens global supply chain resilience. https://t.co/HrzF7Bprsa
#SupplyChain
pharmaceuticalcommerce.com
The acquisition strengthens CEVA’s global project logistics footprint, adding heavy-lift expertise, specialized engineering talent, and integrated solutions across key regions.
0
0
0
Pharma is at an inflection point. At #Trade2025, Bill Roth outlined why accelerating policy change—from MFP and 340B to MDRP—will drive WAC reductions, reshape channels, and spark new debates around direct-to-patient models. https://t.co/k6BG7SRmrX
#Pharma #GTN #MarketAccess
pharmaceuticalcommerce.com
In a wide-ranging keynote on disruption across pharmaceutical channels, Bill Roth, general manager and managing partner of IntegriChain’s consulting business, outlines why 2025 marks the beginning of...
0
0
0
The $405 billion patent cliff is here. Pharma must shift from competition to partnership to survive the massive LOE wave, Cort suggests. Key to winning market access now is deep channel collaboration, provider & patient education. #Trade2025
https://t.co/2B2ooauk0F
pharmaceuticalcommerce.com
BioCare's Ryan Cort outlines the pharmaceutical industry's "unprecedented sea change," driven by over $400 billion in anticipated revenue loss from generics and biosimilars losing exclusivity.
0
0
0
As the FDA ends its phased exemption period for most trading partners, a warning that DSCSA compliance is entering a far more complex era, one shaped by real-time traceability, digital record requirements, and a transition to a 12-digit NDC. #Trade2025
https://t.co/c9daAOVVaM
pharmaceuticalcommerce.com
As the FDA ends its phased exemption period for most trading partners, Two Labs’ Michael Rowe warns that DSCSA compliance is entering a far more complex era—one shaped by real-time traceability,...
0
0
1
The latest from #Trade2025 - Subject matter experts from @CencoraGlobal and Fuze Health explore how modern commercialization models, digital-first pharmacy solutions, and closer provider partnerships are reshaping patient access and adherence. https://t.co/LGrAfmXgRP
pharmaceuticalcommerce.com
Subject matter experts from Cencora and FuzeRx explore how modern commercialization models, digital-first pharmacy solutions, and closer provider partnerships are reshaping patient access and...
0
0
0
#MedicalAffairs is transforming. 🚀 #AI is moving the function from reactive to "precision medical affairs" by turning raw data into actionable insights for targeted HCP engagement. The catch? It’s a human-AI partnership—expertise is still essential. https://t.co/WckVb6zslN
pharmaceuticalcommerce.com
Artificial intelligence is fundamentally transforming medical affairs from a reactive function into a strategic partner by converting disparate data into "precision medical affairs" insights, driving...
0
0
0
Manufacturers, providers, and patients all gain when DTP delivers transparency, speed, and trust across the journey. Learn how this model changes the experience for everyone. Read partner perspective: https://t.co/MhGE3rIAL6
#PharmaInnovation #DigitalHealth
0
0
0
đź’Š Cost isn't the top barrier to medication adherence. New data from Pleio's report notes that knowledge gaps (40.6%) & skills deficits (40.5%) are the top obstacles. https://t.co/HXhfT8NCZB
#Pharma #MedicationAdherence #Healthcare #PatientCare
pharmaceuticalcommerce.com
Analysis determines that emotional barriers, knowledge gaps, and skills deficits are far more disruptive to starting and staying on therapy than commonly perceived financial obstacles.
0
0
0
Strive Pharmacy is building a new 350,000 sq. ft. HQ in Mesa, AZ. The expansion will boost national fulfillment & compounding capacity, & is built to ensure the pharmacy can quickly adapt to patient needs & potential drug shortages. #Pharma #Healthcare
https://t.co/eMGrEBAJb1
pharmaceuticalcommerce.com
The new 350,000 square-foot Mesa hub is expected to expand the compounding pharmacy’s national fulfillment and advanced compounding capabilities.
0
0
0
Big move in pharma trade: 🇺🇸 + 🇬🇧 agree to zero tariffs on drugs + med devices. ▪ UK raises reimbursement levels 25% ▪ NICE framework to undergo major change https://t.co/8nTgn2w6ng
#Pharma #Trade #HealthcarePolicy #DrugPricing
pharmaceuticalcommerce.com
The agreement includes exemptions for UK-produced drugs and medical devices from Section 232 tariffs, but mandates a significant change to the UK's NICE value appraisal framework.
0
0
1
🚨 IRA Price Cuts ARE IN. 🚨 CMS announced a 44% net savings on 15 high-cost Medicare drugs, effective 2027. Major detail: Novo Nordisk's Ozempic/Wegovy negotiated price is down 71% to $274/month. https://t.co/wpxbvqVPRt
pharmaceuticalcommerce.com
The Trump administration has announced new negotiated Medicare prices for a second wave of blockbuster treatments, yielding an estimated $12 billion in savings for 2027, when compared to Medicare’s...
0
0
0
Medicare is expected to unveil negotiated prices for 15 high-cost drugs this week, including GLP-1s like Ozempic & Wegovy. Big shifts ahead for U.S. drug affordability. https://t.co/1oiQAAPUX6
#pharma #Medicare #drugpricing
pharmaceuticalcommerce.com
As the federal government prepares to release newly negotiated Medicare drug prices, weight-loss blockbusters Ozempic and Wegovy remain in the spotlight, while CMS advances a model to cut Medicaid...
0
0
0
The future of pharma is direct. DTP programs let manufacturers own the patient journey—improving speed, data, and outcomes. Discover insights from Gifthealth CEO Chip Parkinson on building trust through smarter access. Read more: https://t.co/AxyLT3Xog6
#PharmaTransformation
0
0
0
The asset isn't the volume of data you collect, it's the quality of your connection. đź’ˇ The future of commercialization is connected intelligence that flows across clinical, access, & engagement systems to hit the patient/HCP at the point of care. https://t.co/FHL9sBq5EH
pharmaceuticalcommerce.com
When intelligence flows across clinical, access, and engagement channels, commercialization shifts from reactive to predictive, giving teams the real-time edge to win in a fast-moving market.
0
0
0
In a must-watch interview with @PharmaCommerce, our Brad Stewart, discusses how pandemic-driven supply chain lessons are shaping the future of US drug production. Learn more: https://t.co/1Fz8bqV28x
#LifeSciences #Innovation
pharmaceuticalcommerce.com
In the first part of his Pharma Commerce video interview, Brad Stewart, BDO’s national life sciences co leader, explains why large-volume, high-need drugs—especially those heavily sourced overseas—...
0
1
2
Manufacturers eyeing CNPVs face tough questions: Which products justify on-shoring—and will they qualify? Only a few vouchers have gone to manufacturing so far, focused on large-volume, high-need drugs, Stewart notes. @BDOhealth
https://t.co/fB2zyD90cB
pharmaceuticalcommerce.com
In the first part of his Pharma Commerce video interview, Brad Stewart, BDO’s national life sciences co leader, explains why large-volume, high-need drugs—especially those heavily sourced overseas—...
0
0
0
A new federal report warns China’s growing control over APIs, KSMs & biomanufacturing poses major risks to the U.S drug supply chain. Meanwhile, lawmakers are revisiting the BIOSECURE Act as pressure builds for onshoring. https://t.co/LYGTqUnZZT
pharmaceuticalcommerce.com
A US-China Economic and Security Review Commission report highlights China’s tightening grip on APIs, biomanufacturing, and R&D services, raising alarms about supply chain vulnerabilities, data...
0
0
0